These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36561177)

  • 21. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.
    Guirakhoo F; Wang S; Wang CY; Kuo HK; Peng WJ; Liu H; Wang L; Johnson M; Hunt A; Hu MM; Monath TP; Rumyantsev A; Goldblatt D
    J Infect Dis; 2022 Oct; 226(8):1401-1406. PubMed ID: 35723969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers.
    Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J
    J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
    Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
    Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination.
    Hein S; Mhedhbi I; Zahn T; Sabino C; Benz NI; Husria Y; Renelt PM; Braun F; Oberle D; Maier TJ; Hildt C; Hildt E
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
    Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
    J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
    Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
    Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
    D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
    Front Immunol; 2022; 13():981693. PubMed ID: 36225911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.